Cargando…
Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study
BACKGROUND: The purpose of this study was to assess changes in gastrointestinal symptom severity in patients with autoimmune disease who were switched from mycophenolate mofetil to enteric-coated mycophenolate sodium (EC-MPS). METHODS: In this national, explorative, single-arm study, 111 patients we...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516030/ https://www.ncbi.nlm.nih.gov/pubmed/26229499 http://dx.doi.org/10.2147/CEG.S81922 |
_version_ | 1782383006094196736 |
---|---|
author | Manger, Bernhard Hiepe, Falk Schneider, Matthias Worm, Margitta Wimmer, Peter Paulus, Eva-Maria Schwarting, Andreas |
author_facet | Manger, Bernhard Hiepe, Falk Schneider, Matthias Worm, Margitta Wimmer, Peter Paulus, Eva-Maria Schwarting, Andreas |
author_sort | Manger, Bernhard |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to assess changes in gastrointestinal symptom severity in patients with autoimmune disease who were switched from mycophenolate mofetil to enteric-coated mycophenolate sodium (EC-MPS). METHODS: In this national, explorative, single-arm study, 111 patients were enrolled and switched to equimolar EC-MPS at baseline. The primary endpoint was change in the Gastrointestinal Symptom Rating Scale (GSRS) total score after 6–8 weeks of treatment (Visit 2). The optional follow-up visit was 6–12 weeks after completion of the study (Visit 2). Secondary endpoints were changes in GSRS subscale score; changes in gastrointestinal-related quality of life measured by the Gastrointestinal Quality of Life Index (GIQLI); and general health-related quality of life (HRQoL) measured by Psychological General Well-Being Index and assessment of overall treatment effect (OTE). Change was evaluated by paired t-tests. RESULTS: At Visit 2, the mean ± standard deviation GSRS total score improved from 2.28±1.13 to 2.02±0.93 points. The change (−0.28±0.92 points, P=0.002) was statistically significant. The change at the follow-up visit (−0.36±0.94 points, P=0.001) was statistically significant and more than the minimal clinical important difference. GSRS subscores showed statistically significant and clinically relevant improvement for abdominal pain (−0.51±1.2 points, P<0.001) and indigestion (−0.42±1.33 points, P=0.002). Overall GIQLI score showed significant improvement from baseline to Visit 2 (−5.8±18.6 points, P=0.002). Per OTE, improvement was reported in 44.1% and 34.2% patients as rated by physicians and patients, respectively. The majority of patients (55%) reported OTE-HRQoL as unchanged. Diarrhea and nausea were the commonly reported adverse events. CONCLUSION: Patients switched to EC-MPS experienced less gastrointestinal symptom burden and showed improvement in HRQoL. |
format | Online Article Text |
id | pubmed-4516030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45160302015-07-30 Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study Manger, Bernhard Hiepe, Falk Schneider, Matthias Worm, Margitta Wimmer, Peter Paulus, Eva-Maria Schwarting, Andreas Clin Exp Gastroenterol Original Research BACKGROUND: The purpose of this study was to assess changes in gastrointestinal symptom severity in patients with autoimmune disease who were switched from mycophenolate mofetil to enteric-coated mycophenolate sodium (EC-MPS). METHODS: In this national, explorative, single-arm study, 111 patients were enrolled and switched to equimolar EC-MPS at baseline. The primary endpoint was change in the Gastrointestinal Symptom Rating Scale (GSRS) total score after 6–8 weeks of treatment (Visit 2). The optional follow-up visit was 6–12 weeks after completion of the study (Visit 2). Secondary endpoints were changes in GSRS subscale score; changes in gastrointestinal-related quality of life measured by the Gastrointestinal Quality of Life Index (GIQLI); and general health-related quality of life (HRQoL) measured by Psychological General Well-Being Index and assessment of overall treatment effect (OTE). Change was evaluated by paired t-tests. RESULTS: At Visit 2, the mean ± standard deviation GSRS total score improved from 2.28±1.13 to 2.02±0.93 points. The change (−0.28±0.92 points, P=0.002) was statistically significant. The change at the follow-up visit (−0.36±0.94 points, P=0.001) was statistically significant and more than the minimal clinical important difference. GSRS subscores showed statistically significant and clinically relevant improvement for abdominal pain (−0.51±1.2 points, P<0.001) and indigestion (−0.42±1.33 points, P=0.002). Overall GIQLI score showed significant improvement from baseline to Visit 2 (−5.8±18.6 points, P=0.002). Per OTE, improvement was reported in 44.1% and 34.2% patients as rated by physicians and patients, respectively. The majority of patients (55%) reported OTE-HRQoL as unchanged. Diarrhea and nausea were the commonly reported adverse events. CONCLUSION: Patients switched to EC-MPS experienced less gastrointestinal symptom burden and showed improvement in HRQoL. Dove Medical Press 2015-07-21 /pmc/articles/PMC4516030/ /pubmed/26229499 http://dx.doi.org/10.2147/CEG.S81922 Text en © 2015 Manger et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Manger, Bernhard Hiepe, Falk Schneider, Matthias Worm, Margitta Wimmer, Peter Paulus, Eva-Maria Schwarting, Andreas Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title_full | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title_fullStr | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title_full_unstemmed | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title_short | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
title_sort | impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a phase iii, open-label, single-arm, multicenter study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516030/ https://www.ncbi.nlm.nih.gov/pubmed/26229499 http://dx.doi.org/10.2147/CEG.S81922 |
work_keys_str_mv | AT mangerbernhard impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT hiepefalk impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT schneidermatthias impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT wormmargitta impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT wimmerpeter impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT paulusevamaria impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy AT schwartingandreas impactofswitchingfrommycophenolatemofetiltoentericcoatedmycophenolatesodiumongastrointestinalsideeffectsinpatientswithautoimmunediseaseaphaseiiiopenlabelsinglearmmulticenterstudy |